A Comparison of the Effects of Invasive Mechanic Ventilation/surfactant Therapy and Non-invasive Nasal-continuous Positive Airway Pressure in Preterm Newborns
Overview
Authors
Affiliations
Aims: This study compared the early-term outcomes of mechanical ventilation (MV)/surfactant treatment with nasal-continuous positive airway pressure (nCPAP) in preterm infants with respiratory distress syndrome (RDS).
Materials And Methods: Data from newborns born between ≥24 and ≤32 weeks of gestation, hospitalized at our newborn intensive care unit, and diagnosed with RDS between January 2009 and February 2012 were analyzed.
Results: Of 193 newborns with RDS who were enrolled in the study, 113 were treated with nCPAP and 80 with MV at a level of 57.5% of nCPAP. Within the study group, 46.3% of the infants were female. The mean gestation of the continuous positive airway pressure (CPAP) group was 29.07 ± 1.99 weeks; that of the MV group was 28.61 ± 2.01 weeks. The birth weight was 1321.1 ± 325.4 g and 1240.3 ± 366.1 g; however, the difference between the two groups was not significant. MV was not required in 54.9% of the patients with nCPAP treatment. Bronchopulmonary dysplasia (BPD) developed in 20 (18.7%) patients in the nCPAP group and 18 (24.4%) patients in the MV group; the difference was not significant (p = .351). Between 2009 and 2012, nCPAP was used at a rate of 33.9, 70.8, 68.4, and 69%. The risk factors for developing BPD were low gestation week, duration of intubation, and proven sepsis (p = .0001, p = .004, and p = .011, respectively).
Conclusions: Early nCPAP treatment in preterm infants (≤32 weeks of gestation) decreases both the need for MV and the use of surfactant, but without a significant effect on BPD development. (No. 2016/324).
Boix H, Fernandez C, Serrano Martin M, Arruza L, Concheiro A, Gimeno A Front Pediatr. 2023; 11:1098971.
PMID: 36896404 PMC: 9989254. DOI: 10.3389/fped.2023.1098971.
Continuous positive airway pressure (CPAP) for respiratory distress in preterm infants.
Ho J, Subramaniam P, Davis P Cochrane Database Syst Rev. 2020; 10:CD002271.
PMID: 33058208 PMC: 8094155. DOI: 10.1002/14651858.CD002271.pub3.